Echocardiographic examination of women previously treated with fenfluramine: Long-term follow-up of a randomized, double-blind, placebo-controlled trial

Archives of Internal Medicine

Volumn 161, Issue 11, 2001, Pages 1429-1436

  Davidoff, Ravin ^a   McTiernan, Anne ^b   Constantine, Ginger ^c   Davis, Kelly D ^c   Balady, Gary J ^a   Mendes, Lisa A ^a   Rudolph, Rebecca E ^b   Bowen, Deborah J ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENFLURAMINE; PLACEBO;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MARKETING; DRUG USE; ECHOCARDIOGRAPHY; EVALUATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOKING CESSATION;

EID: 0034921587     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.11.1429     Document Type: Article

References (23)

1. Postsmoking cessation weight gain preventive intervention with D fenfluramine
2. Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using D-fenfluramine
3. Strategies to minimize weight gain after smoking cessation psychological and pharmacological intervention with specific reference to dexfenfluramine
4. The effect of dexfenfluramine and fluoxetine on weight gain after smoking cessation
5. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
6. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo
7. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
8. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
9. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valvular abnormalities
10. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
11. Echocardiographic design of a multicenter investigation of free-living elderly subjects: The cardiovascular health study
12. Evaluation of aortic insufficiency by Doppler color flow mapping
13. Color Doppler assessment of mitral regurgitation with orthogonal planes
14. Prevention Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine US Department of Health and Human Services interim public health recommendations, November, 1997
15. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation
16. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
17. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults
18. Obesity drugs and the heart
19. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
20. A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone and in combination
21. Long-term weight control study: Conclusions